Document:

Exhibit 10.13

 

 

FUNDING AGREEMENT

 

THIS FUNDING
AGREEMENT dated as of July 5, 2022 (this “Agreement”) is entered into by and between IBI Spikes Ltd., a company incorporated
and existing under the laws of the State of Israel with company no. 51-626743-2 (“Spikes”) and Beamr Imaging Ltd
a company incorporated and existing under the laws of the State of Israel with company no. 514331552
(“Company”).

 

		WHEREAS	Company has requested Spikes to provide it with funds for the purpose of expanding its marketing and other
business growth initiatives upon and subject to the terms and conditions of this Agreement; and

 

		WHEREAS	Spikes has agreed to provide it with such funds upon and subject to the terms and conditions of this Agreement;

 

NOW, THEREFORE, the parties hereby agree
as follows:

 

		1.	DEFINITIONS

 

In this Agreement all capitalized
terms shall have the meanings given to them in Exhibit A of this Agreement (in addition to the definitions included in the
body of this Agreement).

 

		2.	THE PAYMENT AMOUNT; USE OF PROCEEDS

 

		2.1.	The Payment Amount.
Upon and subject to the terms and conditions of this Agreement, within 10 Business Days following the Closing Date, Spikes will provide
the Company with the Payment Amount. The Payment Amount (less the Arrangement Fee) shall be credited to the Account (as defined below,
provided that if such definition includes more than one account, for purposes hereof the amount shall be credited to the first account
listed on Exhibit B). The crediting of such amount to the Account shall constitute conclusive evidence of the receipt of
the full Payment Amount by Company. It being agreed, and Company hereby instructs, that the Arrangement Fee shall be deducted from the
Payment Amount and transferred to Spikes’ own account upon extension of the Payment Amount.

 

		2.2.	The Repayment Amount. In consideration of the funding
pursuant to this Agreement Company shall pay Spikes the Arrangement Fee (which shall be deducted from the Payment Amount advanced to
the Company) and the Repayment Amount. The Repayment Amount shall be paid to Spikes as set out in Section ‎3 below.

 

		2.3.	The Note. As security for Company’s obligation
to pay the Repayment Amount pursuant to this Agreement, Company shall execute and deliver to Spikes a promissory note (שטר
חוב) in the form attached as Exhibit C (the “Note”) as a precondition to the provision
of the Payment Amount. The Note shall constitute an unconditional obligation to pay the Repayment Amount in accordance with the terms
of this Agreement.

 

		2.4.	Use of Proceeds. Company may only use the Payment
Amount proceeds for Company’s marketing or other business growth initiatives, and not for the repayment of debt or for any personal,
family or non-business-related purpose unless otherwise explicitly permitted by Spikes in advance and in writing. Without limiting the
foregoing, Spikes is not bound to monitor or verify the application of the Payment Amount pursuant to this Agreement.

 

		2.5.	Follow-on funding. It is the general intention of
the parties to increase the Payment Amount in the future by additional amounts to be made available by Spikes to the Company, subject
to due diligence, to satisfactory financial results, and subject to the mutual consent of the parties at such future time.

 

     

     

    

 

 

		3.	PAYMENTS

 

		3.1.	Monthly Repayments. Beginning
on the first calendar month following the Closing Date, Company shall make consecutive Monthly Repayments to Spikes until the earlier
to occur of (i) the date Spikes has received from Company the Repayment Amount (subject to the early repayment option according to Section
‎3.3 below); and (ii) the Final Repayment Date. Monthly repayments shall include a portion classified
as return of Payment Amount and the balance to be classified as rev-share (תמלוגים) to Spikes.
The rev-share component of the monthly repayment amounts will be subject to VAT. Notwithstanding the above, Company’s minimum annual
payment during any Annual Calculation Period will not be less than the lower of (a) NIS 1,141,800, and (b) the outstanding Repayment
Amount.

 

		3.2.	Full Repayment. Any amount on account of the Repayment
Amount that has not been paid to Spikes pursuant to Section ‎3.1 above shall be immediately due and payable to Spikes on the Final
Repayment Date (without limiting Spikes’ right to accelerate payments, in certain events, pursuant to Section ‎10.2 below). Additionally,
all other unpaid Obligations owed by Company to Spikes under the Transaction Documents, shall be immediately due and payable to Spikes
on the Final Repayment Date (without limiting Spikes’ right to collect them when due or accelerate payments pursuant to Section ‎10.2
below).

 

		3.3.	Early Repayment. Subject to five (5) business days
of advance written notice to Spikes and subject to the provisions below, Company may repay to Spikes the entire outstanding Repayment
Amount, at any time prior to the Final Repayment Date. Notwithstanding the above:

 

		a.	if early repayment occurs prior to the 12-month anniversary
date of the Closing Date (July 5, 2023), then, a discount of 50% will be applied on the outstanding Rev-Share Amount component of the
outstanding Repayment Amount; or

 

		b.	if early repayment occurs after the 12-month anniversary
of the Closing Date and before the 18-months anniversary date of the Closing Date (November 5, 2023), then, a discount of 35% will be
applied on the outstanding Rev-Share Amount component of the outstanding Repayment Amount.

 

For the purpose of this Section, “Rev-Share
Amount” shall mean the difference between the Repayment Amount and the Payment Amount.

 

		3.4.	Success Consideration. In addition to Company’s payment
obligations under this Agreement, in consideration for Spikes’ successful provision to Company of the Payment Amount, on the Closing
Date, Company shall execute and grant Spikes with a Warrant in the form attached hereto as Exhibit I.

 

		4.	PLACE AND MANNER

 

		4.1.	Place and Manner. All Monthly Repayments shall be
made by Company to Spikes’ account, the details of which are identified in Exhibit H hereto (as may be changed by Spikes
and notified to Company in writing) (“Spikes’ Account”) in immediately available funds in New Israeli Shekels (if Company’s
NCR are in USD, a fixed exchange rate of 1 USD = 3.46 NIS will apply for all foreign exchange calculations) on or before 14:00 (Israel
time) on the relevant payment date. Without derogating from Company’s obligation to make the Monthly Repayments in accordance with
this Section 4, at or prior to execution of this Agreement, Company shall provide Spikes with an account debit instruction (הוראה
לחיוב חשבון) in customary form and up to the Repayment Amount (“ADI”)
duly executed by Company and approved by the relevant bank in relation to Company’s account/s at such bank as identified on Exhibit
B (collectively, the “Account”). Company hereby authorizes Spikes to use, at its sole discretion and without
derogating from Company’s obligation to make the Monthly Repayments, the ADI to debit from the Account all amounts due and outstanding
from time to time under the Transaction Documents. Until termination of this Agreement, Company shall not be permitted to cancel or change,
in any way, the ADI or otherwise cause or permit (whether voluntarily or involuntarily) the ADI to cease to be in full force and effect.
Without limiting the above, it is hereby clarified that (i) collection of amounts by use of the ADI does not derogate from Company’s
obligation to fully and timely pay all amounts due to Spikes pursuant to the Transaction Documents; and (ii) payment shall only be deemed
made when Spikes’ Account has been actually credited with the relevant payment in immediately available funds.

 

    2

     

    

 

 

		4.2.	Monthly Repayments’ Procedure. Within two (2)
days from the end of each month, Company will provide Spikes with monthly bank statements listing all Net Cash Receipts transactions
and an Excel summary (in English) of the monthly in-flows to the bank accounts in a format provided by Spikes, and Spikes will send Company,
within three (3) Business Days from receipt of such Excel summaries and bank statements, a calculation of the amount due, including the
portion to be classified as return of Payment Amount and the portion to be classified as rev-share (תמלוגים)
to Spikes (“Monthly Repayment Statement”). The Payment Amount minus the cumulative returns of Payment Amount portions
shall be referred as “outstanding portion of the Payment Amount”. If Company disagrees with Spikes’ calculations of the amount
due, Company shall notify Spikes within three (3) Business Days from the receipt of Spikes’ notice regarding the calculation of the amount
due (the “Disputed Amount”), and shall provide Spikes with details of Company’s Net Cash Receipts calculations and
other information (in form and substance satisfactory to Spikes) to support Company’s calculation of Net Cash Receipts. Otherwise, Company
shall be deemed to have consented to and agreed to Spikes’ calculation of the amount owed. In the event of a disagreement, Spikes shall
be entitled to receive the uncontested amount and Company and Spikes will work together to come to an agreement on the Disputed Amount
owed in accordance with Section 4.3 below. If the uncontested amount received by Spikes is determined by agreement of the Parties to
be in excess of the Monthly Repayment owed for such month, then subsequent Monthly Repayment(s) shall be reduced by such overpaid amount.
If the uncontested amount received by Spikes is determined to be less than the Monthly Repayment that was due to be made to Spikes for
such month, then the subsequent Monthly Repayment shall be increased by such underpaid amount.

 

		4.3.	Disputed Amount Resolution Mechanism. With respect
to the Disputed Amount as provided under Section 4.2 above, if Spikes disagrees with Company’s calculation of the Net Cash Receipt,
the Parties will attempt to resolve such dispute promptly in an amicable manner by a meeting (which may be executed also by means of
video conferencing) of authorized representatives of both Parties and either party may provide additional documents and/or accounting
opinion to support its calculation. Only if the dispute has not been resolved within 5 Business Days following such meeting, then the
dispute shall be settled by arbitration in accordance with the Israeli Arbitration Law, 1968 held by one agreed arbitrator, and shall
take place in Tel Aviv. If the Parties do not reach an agreement with respect to the identity of the arbitrator, the arbitrator will
be appointed by the Arbitration Institute of the Israel Bar Association. This Section 4.3 is an arbitration agreement in accordance with
the Israeli Arbitration Law 1968.

 

		4.4.	Payment Due Date. A Monthly Repayment, other than
with respect to the Disputed Amount as provided under Section 4.2, should be paid to Spikes up to 3 days following the Monthly Repayment
Statement and in any way no later than 8th day of each month (the “First Due Date”). The Disputed Amount,
if any, should be paid to Spikes no later than within 14 days following the resolution of the applicable dispute (the “Second
Due Date”).

 

		5.	DEFAULT INTEREST

 

If Company fails to pay any amount payable by
it under the Transaction Documents, by the applicable Due Date, interest (“Default Interest”) shall accrue on the overdue
amount from the applicable Due Date up to the date of actual payment at the Default Interest Rate, provided that, with respect to any
Disputed Amount that it is resolved (pursuant to Section 4.2 and 4.3 above) that Spikes’ initial calculations of the applicable Disputed
Amount were correct, the Default Interest with respect to such amount shall accrue from the First Due Date as if such amount was not in
dispute. Any Default Interest accruing under this Section ‎5 shall be immediately payable by Company upon the receipt of a written
demand by Spikes. Default Interest (if unpaid) arising on an overdue amount will be compounded with the overdue amount every thirty (30)
days but will remain immediately due and payable. For the sake of clarity, the amount of Default Interest paid pursuant to the foregoing
shall be in addition to, and not applied towards, the repayment of the Repayment Amount.

 

    3

     

    

 

 

		6.	CLOSING CONDITIONS

 

Prior to the execution of this Agreement, and
as a condition for Spikes’ to provide Company with the funding pursuant to this Agreement: (a) Spikes shall receive, in form and substance
satisfactory to Spikes, the following: (i) a fully-executed copy of this Agreement, together with an executed copy of a board resolution
in form attached hereto as Exhibit F, (ii) a fully-executed Note, (iii) a description of the Company’s intellectual
property and a list of the Company’s Domain Names, as further detailed in Exhibit D attached hereto,(iv) the ADI duly
executed by Company and approved by the relevant bank in relation to the Account; (v) an executed Confidential Information, Invention
Assignment, Non-solicitation and Non-competition Undertaking of each Key Employee, in form attached hereto as Exhibit G
(the “Undertaking”), (vi) confirmation of ownership (אישור ניהול
חשבון) with respect to the Account; and (vii) the executed Warrant in the form attached hereto as Exhibit
I; (b) no Acceleration Event (as defined below) shall have occurred and be continuing or any event, fact or circumstance that
has or could reasonably be expected by Spikes to result in an Acceleration Event; (c) no event or condition shall exist that has had or
could be reasonably expected by Spikes to have a Material Adverse Effect; (d) in Spikes’ reasonable opinion there shall be no legal or
regulatory restriction, prohibition or limitation on its ability to provide the funding and enforce its rights upon the terms and conditions
of this Agreement; and (e) the representations and warranties of Company contained in this Agreement shall be true and correct as if made
on the Closing Date. If any of the conditions precedent described in this Section6 above shall not be met to Spikes’ reasonable satisfaction
on or before the Closing Date, Spikes’ commitment to provide the funding pursuant to this Agreement shall automatically terminate without
any liability to Spikes and without derogating from the continuing effect of the provisions of this Agreement that survive such termination.

 

		7.	REPRESENTATIONS AND WARRANTIES

 

		7.1.	Representations and Warranties. Company represents
and warrants to Spikes as of the date of this Agreement that:

 

		a.	Company is duly incorporated and validly existing under the
laws of the State of Israel and is duly licensed and authorized to operate in each territory in which Company does business;

 

		b.	Company’s main business is research and development or manufacturing
of innovative and high technology products or procedures, in the field of video and photo compression (the “Field of Business”);

 

		c.	Company, after having an opportunity to consult with its
attorneys and financial advisors, has thoroughly read the Transaction Documents and fully understands and agrees to their terms and conditions,
in particular Company expressly confirms that it understands and agrees to: (i) the actual cost of the funding given to it pursuant to
the Transaction Documents; (ii) the payment procedure for the repayment of Obligations due to Spikes under this Agreement; and (iii)
that nonpayment of amounts due to Spikes under the Transaction Documents may result in Default Interest and enforcement procedures against
it, its assets and properties;

 

		d.	all information provided by Company to Spikes in connection
with this Agreement, including the information contained in all exhibits and schedules hereto, is true and correct in all respects;

 

		e.	Company has full power and authority to enter into this Agreement
and the other Transaction Documents, and that this Agreement and the other Transaction Documents are binding and enforceable against
Company in accordance with their terms;

 

		f.	Company is not in default of any agreement under which Company
owes any money in excess of the Threshold Amount or any agreement, the violation or termination of which could have a Material Adverse
Effect;

 

		g.	Company has taken all action and obtained all consents necessary
to authorize the execution, delivery and performance of this Agreement and the other Transaction Documents;

 

		h.	Company (and/or Company’s Subsidiaries as applicable) has
good title to its assets and properties (including intellectual property) and there is no Security on its and its Subsidiaries’ assets
and properties (including intellectual property) other than Permitted Security;

 

		i.	the execution and performance of this Agreement and the other
Transaction Documents shall not conflict with, or constitute a default under, any agreement to which Company is party or by which Company
is bound, or violate any Legal Requirement applicable to Company or Company’s business.

 

    4

     

    

 

 

		j.	all financial statements and other information provided to
Spikes fairly present Company’s financial condition, contain no material misrepresentations or fail to state a material fact necessary
in order to make the statements contained therein not misleading, and there has been no material adverse change in the financial condition
of Company since the date of the most recent financial statements submitted to Spikes;

 

		k.	Company owns, or holds a valid license for, the intellectual
property further detailed in Exhibit D, and any other intellectual property currently used in the conduct of Company’s
business;

 

		l.	Company is in compliance with all Legal Requirements;

 

		m.	Company is not party to, or to Company’s best knowledge threatened
with, any litigation and to Company’s best knowledge is not the subject of any government investigation, and Company has no knowledge
of any pending litigation or investigation or the existence of circumstances that reasonably could be expected to give rise to litigation
or an investigation.

 

		n.	Company does not own any shares or other equity interests
in any corporation, partnership, limited liability company or other entity, except for the Subsidiaries listed in Exhibit E;

 

		o.	Omitted;

 

		p.	all of Company’s assets and properties are in good operating
condition and repair, subject to ordinary wear and tear, and Company has made all economically reasonable and necessary repairs thereto;

 

		q.	each account receivable of Company represents an undisputed,
bona fide and existing, unconditional obligation of the account debtor created by the sale, delivery and acceptance of goods or the rendition
of services in the ordinary course of Company’s business;

 

		r.	Company is able to pay its existing debts (including trade
debts) as they mature;

 

		s.	Each Key Employee is devoting substantially all of his or
her (as applicable) business time to the conduct of the business of Company and has executed a standard IP, confidentiality and non-compete
and non-solicitations undertakings towards the Company, which is attached hereto as Exhibit G;

 

		t.	all of Company’s operating, deposit and investment accounts
are maintained or invested with the financial institutions or other providers (including PayPal, Google and Apple) as currently listed
on Exhibit B, and as it may hereafter be updated or amended as required by Section ‎8.7 below;

 

		u.	the Company does not have plans or intention to change in
any material respect in its current Field of Business;

 

		v.	all of Company’s bank accounts to which Spikes will have
ADI access are identified on Exhibit B;

 

		w.	no Acceleration Event or event that with the passing of time,
giving of notice, or fulfillment of any condition will constitute an Acceleration Event, currently exist;

 

		x.	no event or condition exists that has had or could be reasonably
expected to have a Material Adverse Effect; and

 

		y.	no representation or other statement made by Company to Spikes
in any Transaction Document or any certificate or instrument delivered by Company to Spikes in connection therewith contains any untrue
statement of a material fact or omits facts or information necessary to make any statements made to Spikes not misleading.

 

    5

     

    

 

 

		8.	AFFIRMATIVE COVENANTS

 

From the date of this Agreement and for so long
as any amount is outstanding under the Transaction Documents or any commitment of Spikes is in force, the undertakings in this Section
‎8 shall remain in force.

 

		8.1.	Financial Information. Company shall provide Spikes
with the following reports:

 

		a.	Quarterly Company-prepared consolidated financial statements
and trial balance signed by Company’s CFO or accountant, due as soon as available, but in any event within thirty (30) days after
the end of each quarter, in form and substance satisfactory to Spikes and prepared in accordance with generally accepted accounting principles
in effect in the United States (“GAAP”) or prepared using commonly accepted methods of recording and reporting Company’s
accounting information applied on a consistent basis;

 

		b.	Fiscal year-end financial statements (on a consolidated and
non-consolidated basis) prepared and audited by an independent public accountant, due as soon as available, but in any event within one
hundred-eighty (180) days after the last day of Company’s fiscal year, in form and substance satisfactory to Spikes and prepared in accordance
with GAAP on a consistent basis;

 

		c.	Company’s monthly bank statements, due as soon as available,
but in any event within two (2) days after the last day of each month;

 

		d.	Company’s annual operating projections in form and substance
satisfactory to Spikes (including income statements, balance sheets and cash flow statements presented in a monthly format) for the upcoming
fiscal year, due as soon as available, but in any event no later than thirty (30) days prior to the end of each fiscal year; and

 

		e.	Company’s annual and monthly or bi-monthly tax returns and
filings due within ten (10) days of filing.

 

		8.2.	Additional Financial Information. In addition to the
periodic Financial Reports specified in Section 8.1 above, Company shall provide Spikes with monthly bank statements and reports and
other information as Spikes deems reasonably necessary with regard to the Company’s and/or its Subsidiaries’ accounts receivables
and revenue stream, as shall be reasonably necessary for Spikes in order to determine the Company’s revenue stream. Subject to
certain confidentiality undertakings to be made by Spikes, Company shall make reasonable consents to the availability and transmission
of such information mentioned in this Section 8.2, and, to the extent applicable, shall make commercially reasonable efforts to cause
the financial institution(s) at which Company maintains its operating accounts to provide such information.

 

		8.3.	Omitted.

 

		8.4.	Other Reporting. Company shall provide Spikes promptly
upon receipt of notice thereof, a report of any legal action pending or to Company’s best knowledge threatened in writing against either
Company or any Subsidiary, which is reasonably likely to result in Material Adverse Effect or if Company’s liability with respect
to such legal action is in excess of the Threshold Amount.

 

		8.5.	Existence; Compliance with Laws. Company shall, and
shall cause each of its Subsidiaries to maintain its legal existence and good standing and will maintain in force all licenses and agreements
necessary or appropriate to the conduct of its business. Company shall, and shall cause each of its Subsidiaries to, pay all taxes on
or before the date such taxes are due and shall comply with all Legal Requirements.

 

		8.6.	Inspection Rights. Spikes (either itself or through
its representatives or advisors or a third party auditor) shall have (i) a right to visit and inspect any of the properties of Company
and its Subsidiaries, including a right to examine and copy the books and records of Company and its Subsidiaries from time to time and
coordinated in advance with the Company; and (ii) to discuss Company’s affairs, finances and accounts with the Company’s officers or
managers and its independent public accountant, at such reasonable times to be coordinated with the Company, and as often as Spikes may
reasonably request (but in no event more than twice a month); and (iii) the right to receive, upon request, information with respect
to events that are or may lead to a breach of any negative covenant under Section 9 to this Agreement or any Acceleration Event under
Section 10 of this Agreement, all from time to time during reasonable business hours and subject to coordination in advance with the
Company.

 

    6

     

    

 

 

		8.7.	Financial Accounts. Company shall maintain, and shall
cause each of its Subsidiaries to maintain its accounts listed on Exhibit B (the “Financial Accounts”).
Company shall provide Spikes five (5) days prior written notice before establishing any additional account not listed on Exhibit
B, and at Spikes’ request provide Spikes ADI access (or, if acceptable to Spikes, other similar instrument) to any such account(s).
Upon an Acceleration Event, at Spikes’ request, Company shall make reasonable commercial efforts to cause each bank or financial institution
listed on Exhibit B situated outside of Israel to execute and deliver an account control agreement or other appropriate
instrument in favor of Spikes, in form and substance satisfactory to Spikes.

 

		8.8.	Insurance. Company shall maintain insurance on the
Company’s assets, properties and business in such amounts and of such types as are reasonable and customary for similar businesses. Proof
of insurance must be provided to Spikes within ten (10) days of the Closing Date.

 

		8.9.	Key Employee(s). Company shall (i) use its best efforts
to maintain the engagement with the Key Employee upon a similar scope of engagement as presented to Spikes prior to entering into this
Agreement provided that Company shall be entitled to change each Key Employee’s engagement terms in the ordinary course of business;
and (ii) promptly notify Spikes if the Key Employee (a) terminates his engagement with Company for any reason, or if his engagement with
Company is terminated for any reason, and/or (b) changes his engagement status (including shifting from providing services full-time
to part-time), and/or (c) materially breaches the Undertaking, attached as Exhibit G hereto.

 

		8.10.	Immediate Notices. As soon as practicable, and in
any event within three (3) Business Days after the discovery of an Acceleration Event or the occurrence or existence of an event or circumstance
that has or could reasonably be expected to result in an Acceleration Event (including as a result of the expiry of a grace period) (“Prospective
Acceleration Event”), Company shall provide Spikes with written notice setting forth the facts relating to or giving rise to
such Acceleration Event or Prospective Acceleration Event.

 

		9.	NEGATIVE COVENANTS

 

From the date of this Agreement and until full
repayment of the Repayment Amount pursuant to Section ‎3.2 above, Company, whether directly or through any of its Subsidiaries, will
not do any of the following without the prior written consent of Spikes:

 

		9.1.	Investments. Make any investments in, or payments
or extend any loans or advances to, any Person other than in the ordinary course of Company’s or Subsidiary’s business as currently conducted.

 

		9.2.	Acquisitions; Mergers; Exit Event. Acquire the shares
or other equity interest in, or any assets of, any Person other than in the ordinary course of Company’s or Subsidiary’s business as
currently conducted, or enter into any merger or consolidation with any Person or allow a Liquidation Event to occur. Notwithstanding
the foregoing, (a) a Subsidiary of Company may merge or consolidate with another Subsidiary of Company, and (b) Company shall not be
prohibited from taking any of the actions or transactions listed above in this Section ‎9.2 if the Repayment Amount and all other
Obligations of the Company to Spikes are paid in full or within three (3) Business Days of the closing of the applicable transaction
and this Agreement is terminated as a condition to the consummation of such action or the closing of such transaction. Without derogating
from the foregoing, it is agreed that the Company shall not be required to receive Spikes’ prior consent with respect to an IPO
in the NASDAQ Capital Marked, consummated by Company within 12 months following the Closing Date, in which the Company raises less than
$30M and provided that ALL of the proceeds of such IPO are solely for the benefit of the Company. It is clarified that solely such IPO
shall not be considered as a Liquidation Event for the purpose of this Agreement, including the Warrant.

 

    7

     

    

 

 

		9.3.	Distributions. Make payment (in cash or in kind) to
holder(s) of any convertible promissory note of Company, or make any distributions or pay any dividends to any Person on account of any
shareholdings or other equity ownership interest in Company or any Subsidiary, or make any payment on account of or in redemption, retirement
or purchase of any shares or other equity ownership interest in Company or any Subsidiary, provided that as long as an Acceleration Event
is not continuing, Company may make Permitted Distributions.

 

		9.4.	Bonuses. Pay bonuses to any employee, director or
consultant of the Company or its Subsidiaries unless (i) the amount of bonuses would not result in, or likely lead to, an Acceleration
Event or insolvency of the Company or its Subsidiary, and (ii) the aggregate amount of bonuses in any fiscal year will not exceed the
aggregate amount of bonuses paid in the last fiscal year prior to the Closing Date, or in case the Company revenues increased more than
25% over the prior fiscal year, aggregate bonuses may exceed 110% of the aggregate amount of bonuses paid in the prior fiscal year.

 

		9.5.	Affiliate Transactions. Directly or indirectly enter
into or permit to exist any material transaction with any Affiliate of Company or any Subsidiary, except for transactions in the ordinary
course of Company’s business, upon fair and reasonable terms that are no less favorable to Company than would be obtained in an arms-length
transaction with a non-affiliated Person or non-subsidiary.

 

		9.6.	Dispositions. Convey, sell, lease, transfer or otherwise
dispose of (collectively, a “Disposition”), or permit any of its Subsidiaries to Dispose, all or any part of its assets
and properties, other than: (i) sale of inventory in the ordinary course of business; or (ii) granting of non-exclusive licenses and
similar arrangements for the use of the property of Company or its Subsidiaries in the ordinary course of business.

 

		9.7.	Subsidiaries. Sell any portion of any Subsidiary or
create, form, or acquire any new direct or indirect Subsidiary of Company, other than forming a wholly owned subsidiary of Company, provided
that Spikes will have (i) monthly bank statements of such fully owned subsidiary; and (ii) the Net Cash Receipts shall also include the
Net Cash Receipts of such fully owned subsidiary.

 

		9.8.	Corporate Changes. Company shall not, without the
prior written consent of Spikes which shall not be unreasonably withheld, (i) change, or permit any Subsidiary to change, its state of
incorporation or formation, or (ii) engage in, or permit any Subsidiary to engage in, any business other than the current Field of Business,
(iii) terminate Key Employee’s employment with the Company for any reason, change or allow to change his employment scope (including
shifting from working full-time to part-time) and/or amend, waive or terminate the Undertaking signed by the Key Employee.

 

		9.9.	Indebtedness. Create, incur, assume or be liable
for any Indebtedness, other than Permitted Indebtedness.

 

		9.10.	Negative Pledge. (i) Create, incur, or allow to subsist
any Security over any of the assets or properties of Company or any Subsidiary, except for Permitted Security, and (ii) assign
or convey any right to receive income other than to a fully owned subsidiary of the Company.

 

		9.11.	Subordinated Debt. Other than with respect to the
Permitted Indebtedness, make any payment on any Subordinated Debt, except as permitted under any subordination agreement approved
by and signed by Spikes governing any Subordinated Debt, or amend any provision in any document relating to a Subordinated Debt except
to extend the maturity date.

 

		9.12.	Change of Control. Allow there to occur any Change
of Control unless Company provides advance written notice of such Change of Control to Spikes and, concurrently therewith, Company has
paid Spikes in full for all Obligations, including, but not limited to, the Repayment Amount, and this Agreement is terminated as a condition
to the consummation of such Change of Control.

 

    8

     

    

 

 

		10.	ACCELERATION EVENTS 

 

		10.1.	Acceleration Events. Each of the following events or circumstances shall constitute an “Acceleration
Event” under this Agreement and the other Transaction Documents, if not cured within five (5) Business Days following written
notice by Spikes to Company on such event, or within three (3) Business Days in the case of a payment default as described in Section
‎10.1(a) below:

 

		a.	Company’s failure to pay all or any part of the amounts due
under this Agreement or the other Transaction Documents on the date such amount is due and payable;

 

		b.	Company’s failure to comply with any agreement, term or covenant
set forth in this Agreement or any other Transaction Document;

 

		c.	Company’s breach of any agreement to which Company is a party
or by which it is bound pursuant to which Company has incurred Indebtedness in an aggregate amount in excess of the Threshold Amount;

 

		d.	Company’s failure to comply with any material Legal Requirements
necessary or appropriate to the conduct of its business;

 

		e.	the occurrence of an Insolvency Event;

 

		f.	any representation or statement made or deemed to be made
by Company in this Agreement or the other Transaction Documents or any other document delivered by or on behalf of Company under or in
connection with this Agreement or the other Transaction Documents is or proves to have been incorrect or misleading in any material respect
when made or deemed to be made;

 

		g.	Any Imposition of expropriation or attachment, lien (other
than Permitted Security), or execution or any analogous process in any jurisdiction affects any asset or assets of Company;

 

		h.	Company suspends or ceases to carry on (or threatens to suspend
or cease to carry on) all or a material part of its business except as part of any disposal allowed under this Agreement;

 

		i.	(i) it is or becomes unlawful for Company to perform any
of its obligations under any Transaction Document; (ii) any obligation or obligations of Company under any Transaction Document are not
or cease to be legal, valid, binding or enforceable and the cessation individually or cumulatively materially and adversely affects the
interests of Spikes under the Transaction Documents; or (iii) any Transaction Document ceases to be in full force and effect;

 

		j.	a judgment or judgments for the payment of money in an aggregate
amount in excess of the Threshold Amount shall be entered against Company;

 

		k.	the occurrence or existence of any event or circumstance
that has or could reasonably be expected to have a Material Adverse Effect;

 

		l.	Key Employee: (i) any material breach of Key Employees’
Undertaking, attached as Exhibit G, (ii) if a Key employee resigns from his/her employment with Company for any reason
or his/her employment with Company is terminated for any reason or if Company materially changes Key Employee’s employment status
(including shifting from working full-time to part-time) without Spikes prior written consent; (iii) If Company materially amends, waives
or terminates the Key Employees’ Undertakings (Exhibit G) without prior written consent from Spikes;

 

		m.	the ADI for the Account is cancelled or otherwise ceases
to be full force and effect; or

 

		n.	the occurrence of any of the events and circumstances set
out in this Section ‎10.1 to any Subsidiary of Company.

 

    9

     

    

 

 

		10.2.	Acceleration. On and at any time after the occurrence of an Acceleration Event Spikes shall have
the right by written notice to Company to:

 

		a.	cancel any commitment of Spikes to provide funding under the Transaction Documents whereupon they shall
immediately be cancelled;

 

		b.	declare that all or part of the unpaid balance of the Repayment Amount and all other Obligations be immediately
due and payable, whereupon they shall become immediately due and payable;

 

		c.	date the Note and present the Note to any competent court or execution office for immediate collection;
and/or

 

		d.	exercise any or all of its rights, remedies, powers or discretions under the Transaction Documents and
applicable law.

 

		11.	INDEMNITY; EXPENSE REIMBURSEMENT

 

		11.1.	Indemnity. Company shall indemnify and hold Spikes harmless from any claim, obligation or liability
(including without limitation reasonable attorneys’ fees and expenses) arising out of this Agreement or any other Transaction Document
or the transactions contemplated hereby or thereby, including any claim, obligation or liability arising before, after or in connection
with an Insolvency Event, other than claims or liabilities caused by Spikes’ gross negligence or willful misconduct. The indemnity obligation
hereunder shall survive the termination of this Agreement until all applicable statute of limitation periods as to actions that may be
brought against Spikes have run.

 

		11.2.	Expense Reimbursement. Company shall, within three (3) Business Days of written demand, pay Spikes
all fees, costs and expenses (including attorneys’ fees and costs) incurred in connection with the enforcement of, or the preservation
of any rights under, this Agreement and with any proceedings instituted by or against Spikes as a consequence of it entering into this
Agreement or enforcing its rights.

 

		12.	NOTICES 

 

Unless otherwise provided in this Agreement, all
communications, documents, notices or demands by any party relating to this Agreement or any other Transaction Document shall be in writing
and (except for financial statements and other informational documents which may be sent by registered mail, postage prepaid) shall be
personally delivered or sent by electronic mail to the electronic mail address of the party set forth below, or sent by a recognized overnight
delivery service, registered mail, postage prepaid, return receipt requested, to Company or to Spikes, as the case may be, at its addresses
below:

 

	If to Spikes: 	 	If to Company:
	IBI Spikes Ltd.	 	Beamr Imaging Ltd.
	Address: 9 Ahad Ha’am St. POB 29161, Tel Aviv, Israel 6129101	 	Address: 10 Hamenofim Street, Herzeliya Pituach 4672561, Israel
	Attention: Mr. Gideon Zigelman, CEO 	 	Attention: Mr. Sharon Carmel, CEO
	Telephone
    No.: 	 	Telephone
    No.: 
	Email:
mailto:	 	Email: 
	with a copy (which shall not constitute notice) to: Adv. Oren Ofek Oren_O@IBI.co.il	 	with a copy (which shall not constitute notice) to: Ronen Kantor: rkantor@dtkgg.com

 

The parties hereto may change the address at which
they are to receive notices hereunder, by notice given in the manner provided for herein. Any communication, document, notice or demand
made or delivered by one Person to another under this Agreement will be effective: (i) if personally delivered, on the date delivered;
(ii) if sent by registered mail, five Business Days after being deposited in the post postage prepaid in an envelope addressed to the
intended recipient; and (iii) if by electronic mail, when received in legible form and without any out of office or other similar reply.

 

    10

     

    

 

 

		13.	MISCELLANEOUS

 

		13.1.	Assignments.

 

		a.	Spikes may assign or transfer all or any part of its rights
and obligations under this Agreement and the other Transaction Documents, including grant a participation of any interest in or pledge
any rights and/or obligations under this Agreement and/or the other Transaction Documents (collectively, “Transfer”),
to any Person or Persons, in each case, without the consent of, Company and in such event Spikes will provide a prior notice to Company.
Company shall fully cooperate with Spikes on any Transfer, including at Spikes’ request (i) promptly take all actions and provide all
information, confirmations and documents (including corporate resolutions) that, at Spikes’ sole discretion, are required or desirable
in order to facilitate any Transfer; and (ii) deliver a new ADI duly executed by Company and approved by the relevant account bank in
relation to the Account. Spikes may disclose any information or documents provided to it under this Agreement and the other Transaction
Documents, including any financial, regulatory or business information, to any Person to (or through) whom it Transfers (or may potentially
Transfer) all or any of its rights and/or obligations under this Agreement and the other Transaction Documents and to any of that Person’s
Affiliates, representatives and professional advisors.

 

		b.	Company may not Transfer any right or obligation under this
Agreement and/or the other Transaction Documents without Spikes’ prior written consent.

 

		13.2.	Application of Payments. All payments received or recovered by Spikes shall be applied first to
Obligations consisting of Spikes expenses and any other amount not constituting Default Interest or the Repayment Amount, second to Obligations
consisting of Default Interest (if any), and last to Obligations consisting of the Repayment Amount; provided however, that following
an Acceleration Event, Spikes has the exclusive right to determine the order and manner in which all payments with respect to the Obligations
will be applied.

 

		13.3.	Confidentiality.

 

		a.	Each party (“Recipient”) may have access
to certain non-public, proprietary, competitively sensitive, or private information and materials of the other Party (“Discloser”),
whether in tangible or intangible form (“Confidential Information”). The Recipient shall not disclose the Discloser’s
Confidential Information to any third party, except to its directors, managers, employees, consultants, advisers, agents and investors
on a need-to-know basis, subject to substantially similar written confidentiality undertakings) (collectively, “Representatives”).
Recipient shall be responsible and liable for any acts or omissions of its Representatives with respect to the Discloser’s Confidential
Information. Recipient shall take commercially reasonable measures, at a level at least as protective as those taken to protect its own
Confidential Information of like nature (but in no event less than a reasonable level), to protect the Discloser’s Confidential
Information within its possession or control, from disclosure to a third party. The Recipient shall use the Discloser’s Confidential
Information solely for the purposes expressly permitted under this Agreement. In the event that Recipient is required to disclose Confidential
Information of the Discloser pursuant to any Law, regulation, or governmental or judicial order, the Recipient will, to the extent permitted
by applicable law: (a) promptly notify Discloser in writing of such Law, regulation or order; (b) reasonably cooperate with Discloser
in opposing such disclosure at Discloser’s sole expense; (c) only disclose to the extent required by such Law, regulation or order
(as the case may be). Upon expiration or termination of this Agreement, or otherwise upon written request by the Discloser, the Recipient
shall promptly return to Discloser, or if so requested by Discloser, destroy, Discloser’s Confidential Information which is in
the possession of the Recipient and/or its Representatives and/or that has been provided to them and any copies thereof (or if embodied
electronically, permanently erase it), and certify compliance in writing. Notwithstanding the foregoing, Recipient may retain any Confidential
Information as may be required by law, rule or regulation or by any competent judicial, governmental, supervisory, regulatory or similar
body having authority or in accordance with its internal policies (for backup purposes only), or where the Confidential Information is
contained on the servers of Recipient pursuant to ordinary computer back-up operations.

 

    11

     

    

 

 

		b.	Each party undertakes to keep this Agreement and the other
Transaction Documents (including the contents hereof and thereof) in strict confidence, and not to divulge the terms thereof to any Person
except as necessary to its Representatives, and each party shall remain liable at all times for any acts and/or omissions, in contradiction
or violation of this Section ‎13.3, of Representatives. Notwithstanding, the Company shall be entitled to disclose the terms of this
Agreement to potential investors and financers as part of a due diligence process, subject to such potential investor or financer entering
into a non-disclosure agreement with the Company, and the Company shall be entitled to disclose the terms of this Agreement (and also
provide a copy of such Agreement) to the extent required as part of its initial public offering documentation filed with the United States
Securities and Exchange Commission and published as required by applicable laws. Each party confirms that a breach of this undertaking
may result in irreparable and continuing damage to the other party for which there may be no adequate remedy at law, and therefore the
other party shall be entitled to seek injunctive relief and/or a decree for specific performance, and such other relief as may be proper
(including monetary damages if appropriate) in any competent court. Nothing in this Agreement shall be construed as derogating from any
right or remedy that a party may be entitled to under applicable law. This Section ‎13.3 shall survive termination of this Agreement.

 

		13.4.	Privacy and Use of Information. Company confirms that it was notified that in accordance with the
Israel Protection of Privacy Law of 1981 all of the information provided to Spikes will be used by Spikes in connection with this transaction
and for the purpose of administering the funding pursuant to this Agreement, and that information provided to Spikes hereunder may be
stored pursuant to all Legal Requirements in Spikes’ databases and subject to confidentiality and non-use undertakings, and Company hereby
expressly consents to the forgoing.

 

		13.5.	No Set-off by Company. All payments to be made by Company under this Agreement and the other Transaction
Documents shall be calculated and made without (and free and clear of any deduction for) set-off, and Company hereby fully and finally
waives any right of set-off.

 

		13.6.	Currency. All payments to be made under the Transaction Documents shall be made in New Israeli
Shekels (NIS) unless parties’ otherwise consent. If any amount is received or recovered by Spikes in a currency other than the currency
it is payable in, Spikes may convert such currency to NIS using the foreign exchange conversion for same-day settlement made available
to it by its account bank. Spikes shall not be liable for the rate so obtained and Company hereby fully and finally waives any claim,
demand or cause of action it may have against Spikes in connection with such conversion.

 

		13.7.	Accounts. Subject to applicable law and without derogating from each of the parties’ rights
in any relevant procedure, in any litigation proceedings arising out of or in connection with this Agreement or the other Transaction
Documents, the entries made in the accounts maintained by Spikes, as evidenced by Spikes’ written records, are prima facie evidence
of the matters to which they relate.

 

		13.8.	VAT. All amounts to be payable under this Agreement by Company to Spikes are exclusive of any VAT
and accordingly if VAT is or becomes chargeable on any supply or service made by Spikes to Company under this Agreement, Company must
pay to Spikes an amount equal to the amount of that VAT. For the avoidance of any doubt, the Company shall add VAT to the rev-share (תמלוגים)
portion of Monthly Repayments and to any fee payable under this Agreement to Spikes.

 

    12

     

    

 

 

		13.9.	Amendments; Entire Agreement. This Agreement and the other Transaction Documents may be amended
only by a written record signed by Spikes and Company. All prior agreements, understandings and negotiations are cancelled and superseded
by this Agreement.

 

		13.10.	Counterparts. This Agreement and the other Transaction Documents may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which shall constitute one instrument.

 

		13.11.	Severability. Each provision of this Agreement and the other Transaction Documents shall be severable
from every other provision for the purpose of determining the legal enforceability of any specific provision. In the event that any provision
of this Agreement or the other Transaction Documents is found to be invalid or unenforceable, the remaining provisions shall remain in
full force and effect.

 

		13.12.	Survival of Covenants, Representations and Warranties. All covenants, representations and warranties
made in this Agreement and the other Transaction Documents shall continue in full force and effect so long as any Obligations hereunder
remain outstanding.

 

		13.13.	Spikes’ Authorization. Company authorizes Spikes to use Company’s name and/or logo in Spikes’ promotional
material, including on Spikes’ web site.

 

		13.14.	No Waiver. No failure to exercise, nor any delay in exercising, on the part of either party, of
any right or remedy under the Transaction Documents shall operate as a waiver of any such right or remedy or constitute an election to
affirm any of the Transaction Documents, nor election to affirm any of Transaction Document on the part of either party shall be effective
unless it is in writing. No single or partial exercise of any right or remedy shall prevent any further or other exercise or the exercise
of any other right or remedy. The rights and remedies in each Transaction Document are accumulative and not exclusive of any right or
remedy provided by law.

 

		13.15.	Governing Law; Jurisdiction. This Agreement and the other Transaction Documents (including any
non-contractual obligations arising out of or in connection with this Agreement and/or the other Transaction Documents) shall be exclusively
governed by and construed in accordance with the laws of the State of Israel, without giving effect to any conflict of laws principles
thereof. The courts of Tel-Aviv Jaffa have exclusive jurisdiction to settle any dispute arising out of or in connection with this Agreement
or the other Transaction Documents (including a dispute relating to the existence, validity, or termination of this Agreement or other
Transaction Documents or any non-contractual obligation arising out of or in connection with this Agreement (“Dispute”)).
The parties agree that the courts of Tel-Aviv Jaffa are the most appropriate and convenient courts to settle Disputes and accordingly
no party will argue to the contrary.

 

		13.16.	Termination. This Agreement shall be automatically deemed terminated, with no further actions required,
at such time as Company has paid Spikes in full for all Obligations, including, but not limited to, the Repayment Amount; provided, however,
that Sections ‎ ‎11, 13.3, ‎13.4, ‎13.10, 13.15 and ‎13.16. and any other provision of this Agreement that expressly
survives termination shall continue and survive the termination of this Agreement.

 

***

 

[Signature Page Follows]

 

    13

     

    

 

 

[Signature Page to Agreement]

 

IN WITNESS WHEREOF, the parties have executed
this Agreement as of the first day above written.

 

	/s/ Gideon Zigelman Tal
    Dori	 	/s/ Sharon Carmel
	IBI SPIKES LTD.	 	Beamr Imaging Ltd.
	By: 	Gideon Zigelman and Tal Dori	 	By: 	Sharon Carmel 
	Title:  	CEO, Director	 	Title:  	CEO

 

Attorney Confirmation

 

The undersigned, Adv. Ronen Kantor legal
adviser to Beamr Imaging Ltd. (the “Company”) hereby confirm that that the Company is authorized to sign this
Agreement and the signature of Mr. Sharon Carmel Israeli I.D number on behalf of the Company is in accordance with and
pursuant to a resolution of the Company which was duly adopted and in accordance with the constituting documents of the Company, and
such signatures are binding on the Company for all intent and purposes.

 

	/s/ Ronen Kantor	 	5/7/2022	 
	Name & Signature	 	Date	 

 

    14

     

    

 

 

EXHIBIT A

 

DEFINITIONS

 

The following capitalized and bolded terms
shall have the following meanings:

 

“Acceleration Date” means
the date Spikes gives the Company a notice of acceleration pursuant to Section 10.2 of the Agreement.

 

“Affiliate” means, with
respect to any Person, any Person that owns or controls (as defined in the Israel Securities Law of 1968) directly or indirectly such
Person, any Person that controls or is controlled by or is under common control with such Person, and each of such Person’s senior executive
officers and directors.

 

“Annual
Calculation Period” means each 12 month period during the term of this Agreement, commencing as of the Closing Date.

 

“Arrangement Fee” means
a non-refundable one-time fee of 1.5% of the Payment Amount plus VAT, which shall be deducted from the Payment Amount advanced to the
Company.

 

“Business Day” means a
day (other than a Saturday) on which banks are open for general business in Israel.

 

“Change of Control” means
the occurrence of any of the following events or circumstances:

 

		(a)	the beneficial shareholders of Company at the Closing Date, taken together, cease to hold, directly or
indirectly: (i) more than fifty percent (50%) of the outstanding capital shares or other means of control of Company; or (ii) the issued
shares or other means of control having the right to cast more than fifty percent (50%) of the votes capable of being cast in general
meetings of Company; or

 

		(b)	the beneficial shareholders of Company at the Closing Date cease, directly or indirectly, cease to have
the power (whether by way of ownership or shares, proxy, contract, agency or otherwise) to appoint or remove all or the majority of the
directors or managers or other equivalent authorized persons or officers of Company.

 

“Closing Date” means the
date this Agreement is signed by both Parties.

 

“Default Interest Rate” means
(a) during the period from the Closing Date and until the earlier of the Final Repayment Date or the Acceleration Date (as applicable),
9% per annum; and (b) during the period commencing on the earlier of the Final Repayment Date or the Acceleration Date (as applicable)
and until all Obligations have been fully and finally paid to Spikes, 13% per annum, but in no event more than the maximum amount permitted
under the applicable law.

 

“Designated Officer” means
an officer or manager of Company that Company’s board of directors or comparable governing body has authorized to act for Company. Company
may identify specific individuals as “Designated Officers” on a form Spikes provides from time to time for that purpose.

 

“Final Repayment Date” means
January 5, 2026, i.e. 42nd month anniversary following the Closing Date.

 

“Governmental Authority”
means the government of any jurisdiction, or any political subdivision thereof, whether provincial, state or local, and any department,
ministry, agency, instrumentality, authority, body, court, central bank or other entity lawfully exercising executive, legislative, judicial,
taxing, regulatory or administrative powers or functions of or pertaining to government.

 

    A-1

     

    

 

 

“Indebtedness” means:

 

		(a)	all indebtedness for borrowed money or the deferred purchase price of property or services, including
without limitation, reimbursement and other obligations with respect to surety bonds and letters of credit;

 

		(b)	all obligations evidenced by notes, bonds, debentures or similar instruments;

 

		(c)	all capital lease obligations;

 

		(d)	all contingent obligations (to be deemed the amount equal to the maximum reasonably anticipated liability
or stated amount of the primary obligation in respect of which such contingent obligation is made), including but not limited to, any
direct or indirect liability, contingent or otherwise, with respect to (i) any indebtedness, lease, dividend, letter of credit or other
obligation of another, any such obligation directly or indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by
Company (or in respect of which Company is otherwise directly or indirectly liable); (ii) any obligations with respect to undrawn letters
of credit, corporate credit cards, or merchant services issued for the account of Company; and (iii) all obligations arising under any
interest rate, currency or commodity swap agreement, interest rate cap agreement, interest rate collar agreement, or other agreement or
arrangement designated to protect Company against fluctuation in interest rates, currency exchange rates or commodity prices; or

 

		(e)	any sale, assignment, promise, pledge or commitment of future sales proceeds in exchange for money, property
or services.

 

“Insolvency Event” means:

 

		(a)	Company (i) is unable or admits inability to pay its debts as they fall due, (ii) is deemed to, or is
declared to, be unable to pay its debts under applicable law, (iii) suspends or threatens to suspend making payments on any of its debts,
(iv) by reason of actual or anticipated financial difficulties, commences negotiations with one or more of its creditors with a view to
rescheduling any of its Indebtedness, or (v) is or becomes subject to any Insolvency Proceedings;

 

		(b)	the value of the assets of the Company is less than its liabilities (taking into account contingent and
prospective liabilities) and, as a result, it is deemed insolvent under any applicable law; or

 

		(c)	a moratorium is declared in respect of any Indebtedness of Company (including a stay of proceedings pursuant
to the Israel Insolvency and Rehabilitation Law of 2018).

 

“Insolvency Proceedings”
means any corporate action, legal proceedings or other procedure or step is taken in relation to:

 

		(a)	the suspension of payments, a moratorium of any Indebtedness, an application for a stay of proceedings,
commencement of proceedings (as defined in the Israel Insolvency and Rehabilitation Law of 2018), winding-up, dissolution, administration
or reorganization (by way of voluntary arrangement, scheme of arrangement or otherwise) of Company;

 

		(b)	a composition, compromise, assignment or arrangement with any creditor of Company;

 

		(c)	the appointment of a permanent or temporary liquidator, receiver, administrative receiver, administrator,
compulsory manager or other similar officer in respect of Company or any of its assets or properties;

 

		(d)	enforcement of any Security over any assets or properties of Company; or

 

		(e)	any analogous procedure or step taken in any jurisdiction.

 

“Key Employee” means Mr.
Sharon Carmel

 

“Legal Requirements” means
any statute, ordinance, code, law, rule, regulation, order or other requirement, standard, procedure enacted, adopted or applied by any
Governmental Authority, including, decisions, orders, writs, awards, or injunctions of an arbitrator or a court or other Governmental
Authority.

 

    A-2

     

    

 

 

“Liquidation Event” means
any one of the following:

 

		(a)	the sale or other disposition of all or a majority of the Company’s assets (including the licensing or
sale of a material portion of Company’s intellectual property);

 

		(b)	(i) the termination of employment of Company’s Key Employee(s), or (ii) the termination of employment
of the majority of the senior level management and/or other employees with direct knowledge of, access to or possession of Company’s material
trade secrets, source code or other confidential intellectual property;

 

		(c)	a merger, consolidation or similar transaction, following which the Company is not the surviving entity;

 

		(d)	a merger, consolidation or similar transaction that results in the conversion or exchange of the Company’s
outstanding shares or other means of control into other property, whether in the form of securities, cash or otherwise;

 

		(e)	a winding up or dissolution of Company or Company’s business that provides for the distribution of cash
or other property to Company’s shareholders; or

 

		(f)	a merger, consolidation or similar transaction involving (directly or indirectly) Company that results
in Company’s shareholders having, directly or indirectly, less than a majority of the combined outstanding voting power of the surviving
entity; or

 

		(g)	an Initial Public Offering of the Company and/or its Subsidiary (an “IPO”).

.

“Material Adverse Effect”
means a material adverse change, that affects the Company’s ability to pay any outstanding amounts related to this Agreement when due,
in (i) the business operations, condition (financial or otherwise) or prospects of Company and its Subsidiaries taken as a whole, or (ii)
the ability of Company to repay the Repayment Amount or otherwise perform its Obligations under the Transaction Documents, or (iii) the
rights or remedies of Spikes under any Transaction Document.

 

“Monthly Repayments” means
consecutive monthly payments equal to the Net Cash Receipts multiplied by the Royalty Rate, payable by Company to Spikes until such time
as Spikes receives the Repayment Amount (as defined below), provided however, that Company’s first Monthly Repayment shall be based
on a prorated amount of the Net Cash Receipts from the month in which the Closing Date occurs, calculated by first multiplying the Net
Cash Receipts by the Royalty Rate and then multiplying the resulting sum by a fraction, the numerator of which shall be the number of
days from the Closing Date to the end of such month and the denominator of which shall be the total number of days in such month.

 

“Net Cash Receipts” means
Company’s and its Subsidiaries’ cash receipts (gross collected revenues), after refunds and paid product returns, from all
sales of products or services, and licensing of products (including prepaid licenses). Net Cash Receipts shall include all types of income
which are classified by Company as revenue.

 

“Obligations” means all
amounts due or that become due by reason of this Agreement, including without limitation the Repayment Amount, Default Interest, the Arrangement
Fee and Spikes Expenses by Company to Spikes under the Transaction Documents.

 

“Payment
Amount” an aggregate amount of NIS 3,114,000

 

“Permitted Distributions”
means ______________.

 

“Permitted Indebtedness”
means:

 

		(a)	Indebtedness of Company in favor of Spikes arising under the Transaction Document;

 

		(b)	an Indebtedness of Company secured by a lien described in clause (c) of the defined term “Permitted
Security”, provided such Indebtedness does not exceed the lesser of the cost or fair market value of the equipment financed with
such Indebtedness;

 

		(c)	Subordinated Debt;

 

		(d)	Indebtedness to Company’s trade creditors incurred in the ordinary course of Company’s business; or

 

		(e)	Indebtedness owing to banks and commercial lending institutions on terms acceptable to Spikes.

 

    A-3

     

    

 

 

“Permitted Security” means:

 

		(a)	any Security on Company’s assets or properties existing on the Closing Date and disclosed in writing to
Spikes on or before the Closing Date (excluding Securities to be satisfied with the proceeds of the Payment Amount);

 

		(b)	liens for taxes or other governmental charges or levies, either not delinquent or being contested in good
faith by appropriate proceedings and for which Company maintains adequate reserves;

 

		(c)	purchase money liens (i) on equipment acquired or held by Company incurred for financing the acquisition
of the equipment, or (ii) existing on equipment when acquired, if the lien is confined to such equipment and the proceeds of the equipment;

 

		(d)	leases or subleases and licenses or sublicenses granted in the ordinary course of Company’s business;
or

 

		(e)	a lien a bank may have over an account held with such bank pursuant to its general banking conditions,
provided such right of lien only secures Permitted Indebtedness.

 

“Person” means any individual,
sole proprietorship, partnership, limited liability company, joint venture, trust, unincorporated organization, association, corporation,
institution, public benefit corporation, firm, joint stock company, estate, entity or governmental agency.

 

“Repayment
Amount” means an aggregate amount of NIS 4,172,760

 

“Royalty Rate” means the
Tier 1 Royalty Rate or Tier 2 Royalty Rate, as applicable.

 

“Security” means a mortgage,
charge (whether fixed or floating), pledge, lien, assignment, hypothecation, cautionary note, right to acquire (including an option or
a right of preemption), deposit arrangement, encumbrance, conditional sale, title retention, preferential right, priority, trust arrangement
or other security interest securing any obligation of any Person or any other agreement or arrangement having a similar effect.

 

“Subordinated Debt” means
any debt of Company (including any debt owing by Company to its shareholders) that is subject to a subordination agreement in favor of
Spikes in form and substance satisfactory to Spikes and on terms acceptable to Spikes.

 

“Subsidiary” means at
any time during the term of this Agreement, any corporation, company or partnership in which (i) any general partnership interest or (ii)
more than 50% of the shares or other means of control which by the terms thereof has the ordinary voting power to elect the Board of Directors,
managers or trustees of the entity, at the time as of which any determination is being made, is owned by Company, either directly or through
an Affiliate of Company.

 

“Threshold Amount” means 25% of the Repayment
Amount.

 

“Tier 1 Royalty Rate”
means 12.2%of Net Cash Receipts for the preceding calendar month until cumulative Net Cash Receipts for the Annual Calculation Period
are equal to the Tier 1 Annual Royalty Rate Cap.

 

“Tier 1 Annual Royalty Rate Cap”
means NIS 11,418,000 (or its equivalent in other currency).

 

“Tier 2 Royalty Rate”
means, after the Company has made cumulative payments to the Spikes during any Annual Calculation Period on Net Cash Receipts equal to
the Tier 1 Annual Royalty Rate Cap, 4.75% of Net Cash Receipts for the preceding calendar month for the remainder of such Annual Calculation
Period.

 

“Transaction Documents”
means this Agreement, the Note and all Exhibits, Schedules, Appendices, Attachments, and other documents attached hereto, and any modification
or amendment thereof.

 

    A-4

     

    

 

 

EXHIBIT B

 

Financial Accounts & the Account Subject
to ADI

  

 

[Intentionally
omitted pursuant to Regulation S-K, Item 601(a)(5)] 

 

 

 

 

 

 

    B-1

     

    

 

 

EXHIBIT C 

 

Form of Note

 

Date: _________________

 

PROMISSORY NOTE

 

FOR VALUE RECEIVED, the undersigned, [_________________],
company incorporated and existing under the laws of the State of Israel with company no. [_________________]
(the “Company”), hereby promises to pay to the order of IBI Spikes Ltd., a company incorporated and existing
under the laws of the State of Israel with company no. 51-626743-2 (the “Spikes”), upon demand from Spikes, the sum of
NIS [_________________] (the “Repayment Amount”) pursuant to a certain
Funding Agreement, to which this Promissory Note is attached as an exhibit, signed between the Company and Spikes on [___________]
as may be amended or modified from time to time (the “Agreement”). Default Interest (as defined in the Agreement) shall
be added to the Repayment Amount in accordance to the terms of the Agreement.

 

The Repayment Amount (and any Default
Interest) is to be paid to Spikes’ account at: Bank Hapoalim, account number:  or such other location as Spikes
may designate in writing to the Company.

 

Payment of the Repayment Amount (and any Default
Interest) by the Company shall not be the subject of any set-off, withholding or counterclaim by the Company for any reason whatsoever
and the Company hereby fully and finally waives any right to the same.

 

This Promissory Note is unconditional, unlimited
in time and assignable by Spikes.

 

The Company hereby expressly waives releases and
exempts Spikes from any and all obligations that are imposed on a holder of a promissory note under applicable law, including presentment,
protest and notice of protest, demand and notice of demand, and nonpayment and notice of nonpayment of this Promissory Note, and expressly
agrees that this Promissory Note, or any payment hereunder, may be extended from time to time without in any way affecting the liability
of the Company. Furthermore, the Company hereby waives any and all rights and defenses vested in it under the Israeli Bills Ordinance
[New Version] (“Bills Ordinance”), including specifically any prescription claim pursuant to section 96 of the Bills
Ordinance, and/or under any other provisions of any other applicable law.

 

The Company represents to Spikes that it has full
power, authority and legal right to execute and deliver this Promissory Note and that the debt hereunder constitutes a valid and binding
obligation of the Company.

 

This Promissory Note may be amended or modified
only by a written document signed by the Company and Spikes.

 

This Promissory Note shall be governed in accordance
with the laws of the State of Israel.

 

	 	 
	[Name of Company]	 

 

By:

 

Title:

 

Attorney Confirmation

 

The undersigned, Adv. ___________________ legal
adviser to ________________ (the “Company”) hereby confirm that that the Company is authorized to sign this Promissory
Note and the signature of __________________Israeli I.D number/Passport number _________________and of _________________ Israeli I.D number/Passport
number __________________ on behalf of the Company is in accordance with and pursuant to a resolution of the Company which was duly adopted
and in accordance with the constituting documents of the Company, and such signatures are binding on the Company for all intent and purposes.

 

		 		 
	Name & Signature	 	Date	 

 

    C-1

     

    

 

 

EXHIBIT D

 

Intellectual Property Description; Domain List
Names

 

 

[Intentionally
omitted pursuant to Regulation S-K, Item 601(a)(5)]  

 

 

 

 

 

 

 

 

    D-1

     

    

 

 

EXHIBIT E

 

Subsidiaries

 

Beamr Inc- USA

Beamr Imaging RU- Russia

 

 

 

 

 

 

 

    E-1

     

    

 

 

EXHIBIT F

 

Company’s Board Resolution

 

 

 

 

 

 

 

 

 

 

 

    F-1

     

    

 

 

EXHIBIT G

 

Key Employee Undertaking

 

 

[Intentionally
omitted pursuant to Regulation S-K, Item 601(a)(5)]  

 

 

 

 

 

 

 

    G-1

     

    

 

 

Exhibit H

 

Spikes’ Account

 

 

[Intentionally
omitted pursuant to Regulation S-K, Item 601(a)(5)]  

 

 

 

 

 

 

 

    H-1

     

    

 

 

Exhibit H

 

Warrant 

 

 

 

 

 

 

 

 

 

H-2Exhibit 10.14

 

THIS WARRANT AND ANY SECURITIES THAT MAY BE ISSUED
UPON EXERCISE THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)
OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THE SECURITIES MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED EXCEPT
(1) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OR (2) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
SECURITIES ACT, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS OF THE STATES AND OTHER JURISDICTIONS IN ACCORDANCE WITH
ALL APPLICABLE instructions of the company’s articles of association, AND IN THE CASE OF
A TRANSACTION EXEMPT FROM REGISTRATION (OTHER THAN PURSUANT TO RULE 144(k), PROVIDED THAT THE COMPANY HAS RECEIVED CUSTOMARY REPRESENTATIONS
CERTIFYING AS TO THE AVAILABILITY OF SUCH RULE 144(k)), UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY
TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH OTHER APPLICABLE LAWS.

 

WARRANT TO PURCHASE SHARES

OF

BEAMR IMAGING LTD.

 

THIS WARRANT issued as of July 5, 2022 (the
“Effective Date”) certifies that, in exchange for the payment of the Payment Amount (the “Payment”),
as such term is defined in that certain Funding Agreement dated July 5, 2022 (the “Funding Agreement”), IBI Spikes
Ltd., a company incorporated and existing under the laws of the State of Israel, having its principle of business at 9 Ahad Ha’am
St., Tel Aviv, Israel (the “Holder”) is entitled, upon provision of the Payment, to subscribe for and purchase from
Beamr Imaging Ltd., a company incorporated and existing under the laws of the State of Israel, having its principle of business at 8 Hamanofim
Street, Herzeliya, Israel (the “Company”), the Warrant Shares at the Exercise Price (as such terms are defined below),
subject to the provisions and upon the terms and conditions hereinafter set forth in this Warrant.

 

1. Definitions.

 

As used herein, unless the context
requires otherwise, the following defined terms shall have the meaning ascribed to them in this section as follows:

 

“Articles” shall mean the Amended
and Restated Articles of Association of the Company in effect from time to time, a copy of which should be provided to Holder upon issuance
of this Warrant.

 

“Qualified Financing” shall
mean a financing round consummated by the Company, in one or a series of related transactions, in which the Company issues securities
of a preferred class or series, in consideration for an aggregate investment of at least US$10,000,000 (Ten Million United States Dollars)

 

    

     

    

 

“Liquidation Event”
shall be as defined in the Funding Agreement, except with respect to (a) an IPO which shall be as defined in this Warrant, and (b) the
termination of employment of a Key Employee (as defined in the Funding Agreement) or the majority of the employees, which shall not be
considered a Liquidation Event for the purpose of this Warrant.

 

“IPO” shall
mean an underwritten public offering of ordinary shares of the Company on TASE, NASDAQ, NYSE or on any other prominent national stock
exchange, excluding an IPO in the NASDAQ Capital Market, consummated by Company within 12 months following the Effective Date, in which
the Company raises less than $30M and provided that ALL of the proceeds of such IPO are solely for the benefit of the Company. It is clarified
that solely such IPO shall not be considered as an “IPO” for the purpose of this Warrant (the “Qualified IPO”).

 

“Realization Event”
shall mean either (a) an IPO; or (b) a Liquidation Event.

 

“Warrant Shares”
shall mean fully paid and non-assessable Company’s shares of the most senior class of shares issued at the applicable Financing,
or in case the exercise is not upon a Financing, then the most senior class of share existing immediately prior to the exercise of this
Warrant, or in case the exercise is upon an IPO ordinary shares, having all rights, privileges and preferences attached to such class
of shares in accordance with the Articles.

 

2. Number
and Class of Warrant Shares; Exercise Price.

 

(a) Number
of Warrant Shares. Subject to and upon the provision of the Payment to the Company, the Holder shall be entitled to purchase Warrant
Shares in an amount equivalent to 0.5% of the issued and outstanding share capital of the Company (on a fully diluted basis) as of the
date hereof, i.e. 327,811 Warrant Shares.

 

(b) Exercise
Price. The Exercise Price for each Warrant Share, subject to adjustments pursuant to the provisions of Section 5 herein, shall be
as follows (the “Exercise Price”):

 

		(i)	if a Qualified Financing occurs within 12 months following the Effective Date, the Exercise Price for
each Warrant Share, will be the price per share in such Qualified Financing, less a 20% discount.

 

		(ii)	if a Non-Qualified Financing occurs, the Holder shall have the right (but not the obligation) to elect,
by delivery of written notice to the Company no later than thirty (30) days from the receipt of a written notice from the Company, to
determine that the Exercise Price for each Warrant Share, will be the price per share in such Non-Qualified Financing, less a 20% discount.

 

		(iii)	In the event that the Company has not consummated by 12 months following the Effective Date a Qualified
Financing or a Realization Event, Holder shall have the right (but not the obligation) to elect, by delivery of written notice to the
Company no later than thirty (30) days from the receipt of a written notice from the Company, to determine that the Exercise Price for
each Warrant Share, will be according to the below formula: a price per share which represents a pre-money valuation of the Company of
US$ 62,500,000 divided by the then of the issued and outstanding share capital of the Company (on a fully diluted basis).

 

		(iv)	Unless an Exercise Price was previously determined in accordance with this Section 2(b), and subject to
Section 3(b) below, if a Realization Event happens before a Qualified Financing, the Exercise Price for each Warrant Share, will be the
price per share in the applicable Realization Event, less a 20% discount.

 

		(v)	In the event that the Company has consummated a Qualified IPO, the Holder shall have the right (but not
the obligation) to elect, by delivery of written notice to the Company no later than thirty (30) days from the receipt of a written notice
from the Company, to determine that the Exercise Price for each Warrant Share, will be the price per share in such Qualified IPO.

 

    2

     

    

 

3. Method
of Exercise; Substitution Options.

 

(a) Exercise.
Until the earlier of (a) the lapse of 10 years period after the Effective Date, or (b) the occurrence of a Liquidation Event, the purchase
rights represented by this Warrant may be exercised by the Holder, by the surrender of this Warrant (with the Notice of Exercise form
attached hereto as Exhibit A duly executed) at the principal office of the Company, as conditional by the final and irrevocable
payment to the Company, by cash or wire transfer of immediately available funds, of an amount equal to the applicable aggregate Exercise
Price of the Warrant Shares in their entirety.

 

(b) Conditional
Exercise. In the event that the Holder intends to exercise this Warrant with respect to a Realization Event, the Holder shall be entitled
to condition such exercise on the consummation of a Realization Event and shall indicate as such on the Notice of Exercise form attached
hereto as Exhibit A, and the Holder will only be required to pay the applicable aggregate Exercise Price at such time as
the Realization Event is consummated. The Company agrees to provide the Holder with a prior notice of a Realization Event in substantially
the same manner and at the same time as shall be given to the Company’s shareholders.

 

(c) Share
Certificates. In the event of any exercise of the rights represented by this Warrant, certificates for the amount of Warrant Shares
so purchased shall be delivered to the Holder within ten (10) days, and, unless this Warrant has been fully exercised with respect to
each applicable Payment in accordance with Section 3(a) hereof, a new Warrant representing the balance of the Warrant Shares with respect
to which this Warrant shall not have been exercised shall also be issued to the Holder within such time.

 

4. Share
Fully Paid; Reservation of Shares. All of the Warrant Shares issuable upon the exercise of the rights represented by this Warrant
will, upon issuance and receipt of the Exercise Price therefore, be fully paid and non-assessable, and free from all liens and charges
with respect to the issue thereof. At all times when this Warrant may be exercised under Section 3 herein, the Company shall have authorized
and reserved for issuance sufficient shares of its Warrant Shares to provide for the exercise of the rights represented by this Warrant.

 

5. Adjustments.
The number and kind of securities purchasable upon the exercise of this Warrant and the Exercise Price payable therefor shall be subject
to adjustment from time to time upon the occurrence of certain events, as follows:

 

(a) Reclassification.
In case of any reclassification or change of the class of Warrant Shares issuable at such time (other than a change in nominal value,
or as a result of a subdivision or combination), the Company shall execute a new Warrant, providing that the Holder shall have the right
to exercise such new Warrant, and procure upon such exercise and payment of the same aggregate Exercise Price, in lieu of such class of
Warrant Shares theretofore issuable upon exercise of this Warrant, the kind and amount of shares, other securities, money and property
receivable upon such reclassification or change, by a holder of an equivalent number of such class of Warrant Shares. Such new warrant
shall provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section
5. The provisions of this subsection (a), shall similarly apply to successive reclassifications or changes subject to the terms hereof
and under the Company’s Articles.

 

    3

     

    

 

(b) Share
Splits, Dividends, Combinations and Reorganizations. In the event that the Company shall at any time subdivide the outstanding class
of Warrant Shares or shall issue a share dividend on its outstanding class of Warrant Shares the number of Warrant Shares issuable upon
exercise of this Warrant immediately prior to such subdivision or to the issuance of such share dividend shall be proportionately increased,
and the Exercise Price shall be proportionately decreased. In the event that the Company shall at any time combine the outstanding shares
of the class of Warrant Shares the number of shares of the class of Warrant Shares issuable upon exercise of this Warrant immediately
prior to such combination shall be proportionately decreased, and the Exercise Price shall be proportionately increased, effective at
the close of business on the date of such subdivision, share dividend or combination, as the case may be.

 

(c) General
Protection. The Company will not by amendment of its Articles or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issuance or sale of its securities or any other voluntary action, avoid or seek to avoid the observance or performance of
any of the terms to be observed or performed hereunder, but will at all times in good faith assist in the carrying out of all provisions
hereof and in taking of all such actions and making all such adjustments as may be necessary or appropriate in order to protect the rights
of the Holder against any impairment.

 

6. Notice
of Adjustments. Whenever the number of shares of the class of Warrant Shares purchasable hereunder or the Exercise Price thereof
shall be adjusted pursuant to Section 5 hereof, the Company shall provide prior written notice to the Holder setting forth, in reasonable
detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the
number and class of shares of the class of Warrant Shares which may be purchased and the Exercise Price therefore after giving effect
to such adjustment.

 

7. Representations
and Covenants of the Company. The Company represents and covenants as follows:

 

(a) all
corporate actions on the part of the Company, its officers, directors and shareholders necessary for the sale and issuance of the Warrant
and the Warrant Shares and the performance of the Company’s obligations hereunder have been taken and are effective as of the date hereof;

 

(b) the
execution and delivery of this Warrant will not, and the issuance of the Warrant Shares upon exercise of this Warrant in accordance with
the terms hereof will not be, inconsistent with the Articles, do not and will not to the Company’s knowledge, contravene any law, regulation,
judgment or order applicable to the Company, and, except for consents that have already been obtained by the Company, do not to the Company’s
knowledge, conflict with any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument of which
the Company is a party to and by which it is bound or require the consent or approval of, the giving of notice to, the registration with
or the taking of any action in respect of or by, any federal, state or local government authority or agency or other person;

 

(c) all
necessary consents of third parties with respect to the issuance of this Warrant and the Warrant Shares upon exercise thereof have been
obtained, and the Company has no outstanding issuance obligations, rights of first offer, pre-emptive or participation rights, anti-dilution
rights or other similar rights with respect to the issuance of this Warrant and the Warrant Shares upon exercise thereof, or any such
rights have been exercised, waived or cancelled.

 

    4

     

    

 

7A.Representations
and Covenants of the Holder. The Holder represents and covenants as follows:

 

(a)  No
Conflict. The execution and delivery of this Warrant do not and will not, and the issuance of the Warrant Shares in the name of the
Holder upon exercise of this Warrant in accordance with the terms hereof, will not contravene any law, regulation, judgment or order applicable
to the Holder, and do not and will not conflict with or contravene any provision of, or constitute a default under, any indenture, mortgage,
contract or other instrument of which the Holder is a party or by which it is bound or require the consent or approval of, the giving
of notice to, the registration with or the taking of any action in respect of or by, any federal, state or local government authority
or agency or other person;

 

(b) Purchase Entirely
for Own Account. This Warrant, the Warrant Shares and the shares issued upon conversion thereof (collectively, the “Purchased
Securities”) will be acquired for investment for the Holder’s own account, not as a nominee or agent, and not with
a view to the resale or distribution of any part thereof, and the Holder has no present intention of selling, granting any participation
in, or otherwise distributing the same. The Holder does not presently have any contract, undertaking, agreement or arrangement to sell,
transfer or grant participation rights to any person with respect to any of the Purchased Securities. The Holder has not been formed for
the specific purpose of acquiring the Purchased Securities.

 

(c)  Investment
Experience. The Holder is an investor in securities of companies in the development stage and acknowledges that it is able to fend
for itself, can fully evaluate and bear the economic risk of its investment, and has such knowledge and experience in financial or business
matters that it is capable of evaluating and understanding the merits and risks of the investment in the Purchased Securities.

 

(d)  Restricted
Securities. The Purchased Securities have not been and will not be registered under the Securities Act or any state securities laws
and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless an
exemption from such registration requirements is available. Holder is aware that, except as set forth in the Rights Agreement, the Company
is under no obligation to effect any such registration or to file for or comply with any exemption from registration.

 

(e)  Lock-up
Undertaking. The Warrant Shares may be subject to a 180 lock up undertaking towards the underwriter of the Company in the IPO, and
the Holder hereby agrees that such Warrant Shares, upon exercise of this Warrant, shall be subject to such lock up undertaking and to
sign and execute any and all lock up agreement provided by the underwriter in such IPO, provided other shareholders of the Company sign
the same lock up agreement.

 

8. Transfer
of Warrant. This Warrant may not be transferred, in whole or in part, without the Company’s prior written consent, other
than to a person that would be considered a Permitted Transferee of the Holder pursuant to the Company’s Articles of Association,
provided that any such transfer shall be subject to the same restrictions applicable to the transfer of shares to Permitted Transferees
under the Company’s Articles of Association. All transfers of this Warrant or the underlying Warrant Shares shall be accompanied
by an executed share transfer deed in the form of transfer attached hereto as Exhibit B. Notwithstanding the above, if the
transfer or assignment of this Warrant is made together with the transfer or assignment of the Funding Agreement, such transfer or assignment
shall be solely subject to the provisions of Section 13.1 of the Funding Agreement.

 

    5

     

    

 

9. Rights
of Shareholders. Without derogating from the Holder’s rights pursuant to the Funding Agreement, the holder of this Warrant
shall not be entitled, as a Warrant holder, to vote or receive dividends or be deemed the holder of the Warrant Shares or any other securities
of the Company which may at any time be issuable upon the exercise of this Warrant for any purpose, nor shall anything contained herein
be construed to confer upon the holder of this Warrant, as such, any of the rights of a shareholder of the Company, including without
limitation, any right to vote for the election of directors or upon any matter submitted to shareholders at any meeting thereof, or to
give or withhold consent to any corporate action (whether upon any recapitalization, issuance of share, reclassification of share, change
of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or to receive dividends or subscription
rights or otherwise until the Warrant shall have been exercised and the Warrant Shares purchasable upon the exercise hereof shall have
become deliverable, as provided herein. So long as the Holder holds this Warrant and/or any of the Warrant Shares, the Company shall afford
to the Holder the same access to information concerning the Company as would be afforded to a holder of the class of the Warrant Shares
under applicable law, the Articles and/or the Company’s Shareholders Agreement, if any.

 

10. Expiration
of Warrant. Subject to Section 3(a) above, this Warrant shall expire and shall no longer be exercisable upon the earlier to occur
of:

 

		(a)	the lapse of 10 years following the Effective Date; or

 

		(b)	a Liquidation Event, provided however, that this provision
shall not affect the right of the Holder to exercise this Warrant pursuant to Section 3(a) hereof prior to the Liquidation Event.

 

The Company shall provide the
Holder with written notice prior to the consummation of a Realization Event or the payment of any dividend payable to the holders of the
class of the Warrant Shares in the same manner and at the same time as shall be provided by the Company to its shareholders.

 

11. Notices.
All notices and other communications required or permitted hereunder shall be in writing, shall be effective when given, and shall in
any event be deemed to be given upon receipt or, if earlier, (a) five (5) days after deposit with a reputable postal service, if delivered
by first class mail, postage prepaid, (b) upon delivery, if delivered by hand, (c) three (3) business days after the business day of deposit
with Federal Express or similar internationally recognized overnight courier, freight prepaid, or (d) one (1) business day after the business
day of facsimile transmission, or electronic mail delivery, if delivered by facsimile transmission or electronic mail with copy by first
class mail, postage prepaid, and shall be addressed (i) if to the Holder, at the Holder’s address as set forth in the preamble above
and (ii) if to the Company, at the address of its principal corporate offices (attention: Chief Executive Officer) or at such other address
as a party may designate by ten (10) days advance written notice to the other party pursuant to the provisions above.

 

12. Governing
Law. This Warrant and all actions arising out thereof or in connection therewith shall be exclusively governed by and construed
in accordance with the laws of the State of Israel, without regard to the conflicts of law provisions. Any dispute arising under or in
relation to this Warrant shall be resolved exclusively in the competent courts of Tel Aviv, Israel, and each of the parties hereby submits
irrevocably to the exclusive jurisdiction of such courts.

 

    6

     

    

 

13. Power
of Warrant. Together with the Funding Agreement and the Transaction Documents (as defined therein), this Warrant and the Exhibits
hereto constitute the full and entire understanding and agreement between the Company and the Holder and are independent of, and supersede,
any other agreement or instrument with regard to the subject matters hereof and thereof.

 

14. Amendment;
Waiver. Any term of this Warrant may be amended and the observance of any term may be waived (either generally or in a particular
instance and either retroactively or prospectively) only with the written consent of the Company and the Holder.

 

15. Successors
and Assigns. The provisions hereof shall inure to the benefit of and be binding upon the successors, assigns, heirs, executors,
and administrators of the parties hereto. Subject to Section 8 avboe, none of the rights, privileges, or obligations set forth in, arising
under, or created by this Warrant may be assigned or transferred by either party hereto without the prior consent in writing of the other
party which consent shall not be unreasonably withheld.

 

16. Tax;
Withholding. Any tax imposed in respect of this Warrant or the Warrant Shares, including, but not limited to, in respect of the
grant of the Warrant, and/or the exercise of the Warrant into Warrant Shares, and/or the transfer, waiver, or expiration of the Warrant
and/or Warrant Shares, and/or the sale of Warrant Shares, shall be borne solely by the Holder. In the event that the Company is required
under applicable law, as reasonable detemined by its legal counsel, to withhold any tax as a result of the exercise of this Warrant and/or
the issuance of the Warrant Shares underlying the Warrant, the Company shall be entitled to withhold such taxes in accordance with applicable
law, provided, however, that if Holder provides the Company with a valid certificate of exemption from tax withholding or a determination
applying a reduced withholding tax rate or any other instructions regarding the payment of withholding taxes issued by the Israel Tax
Authority (each, a “Tax Certificate”), then such withholding (if any) shall be made only in accordance with the provisions
of such Tax Certificate. Prior to making any tax withholding payment, the Company shall advise Holder in writing of such proposed payment
in order to allow Holder to present to the Company a Tax Certificate. If any deduction or withholding payment is so made by the Company,
then, promptly after paying any such amount, Company shall deliver to Holder evidence reasonably satisfactory to the Holder of such deduction,
withholding or payment and of the remittance thereof to the relevant taxing authority. The Company will reasonably cooperate with Holder
in connection with information and documentation reasonably required by Holder in connection with credits, exemptions, or rebates, or
other benefits to be obtained by Holder in connection with such withholding payments made by the Company, which credits, exemptions, rebates,
or other benefits shall be property of the Holder. Notwithstanding the foregoing, to the extent the Company is required under applicable
law to withhold any taxes as a result of the issuance of the Warrant Shares underlying the Warrant, the company shall issue the Warrant
Shares upon the exercise of this Warrant only after the earlier of (i) receipt of a Tax Certificate provides full tax exemption with respect
to such issuance of the Warrant Shares, or (ii) receipt of an amount in cash representing the amount of tax which the Company is required
to withhold upon the issuance of such Warrant Shares underlying the Warrant under Israeli law.

 

    7

     

    

 

17. No
Rights as Shareholder. Except as set forth herein, the Holder shall not have any rights as a shareholder of the Company with regard
to the Warrant Shares prior to the exercise of this Warrant, and then solely with respect to such Warrant Shares which have been purchased
upon such exercise.

 

18. No
Fractional Interest. No fractional shares will be issued in connection with any exercise hereunder, but in lieu of such fractional
shares which would otherwise be issuable the number of shares shall rounded up to the nearest whole number.

 

Issued this 5 day of July, 2022.

 

/s/ Sharon Carmel

 

 

Beamr Imaging Ltd.

 

By: Sharon Carmel, CEO

 

    8

     

    

 

EXHIBIT A

NOTICE OF EXERCISE

 

To: ___________ Ltd.

 

_______ St.

 

_________

 

Attn: ____________

 

	1.	The undersigned hereby elects to purchase [number] [_] shares of [class of shares]
(the “Shares”) of __________ Ltd. pursuant to the terms of the attached Warrant and tenders herewith payment in full
for the purchase price of the shares being purchased, together with all applicable transfer taxes, if any.

 

	2.	Please issue a certificate or certificates representing said [_] Shares in the
name of the undersigned.

 

	3.	Please record in the Company’s internal share register, the undersigned
representing the owner, of the said [_] Shares, as follows:

 

 

 

(Name and Signature)

 

 

(Amount)

 

 

(Address)

 

    A-1

     

    

 

EXHIBIT B

FORM OF
TRANSFER

 

(To be signed only upon transfer of Warrant)

 

FOR VALUE RECEIVED, the undersigned hereby
sells, assigns and transfers unto _______________________________________________ the right represented by the attached Warrant to purchase
____________ [_] shares of ___________ Ltd. (the “Warrant”) to which the attached Warrant relates, and appoints ______________
Attorney to transfer such right on the books of __________ Ltd., with full power of substitution in the premises. The undersigned further
represent that the transfer is made in accordance with the terms of the Warrant.

 

	Dated:_______________________
    	 	 
	 	 	 
	 	By:	 
	 	Name:	 
	 	 	 
	 	 	Address: [__________________]
	 	 	 
	 	 	                  [__________________]

 

And we, the undersigned,
agree to the transfer of said rights to which the Warrant relates, and agree to be bound by the terms and conditions of the Warrant.
The undersigned further represent that the transfer is made in accordance with the terms of the Warrant.

 

	 	 	Address: [__________________]
	 	 	 
	 	 	                  [__________________]
	 	 	 
	 	 	                [fax:________________]
	 	 	 
	 	 	                [e-mail:______________]

 

Acknowledged and confirmed by the Company.

 

	 	
	 	Date:	 
	 	 	 
	 	By:	 
		Name:	 

 

 

B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]